Suppr超能文献

子痫前期的预测和一级预防。

Prediction and primary prevention of pre-eclampsia.

机构信息

Centre for Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, UK.

出版信息

Best Pract Res Clin Obstet Gynaecol. 2011 Aug;25(4):419-33. doi: 10.1016/j.bpobgyn.2011.02.008. Epub 2011 Mar 30.

Abstract

Pre-eclampsia is associated with increased maternal and perinatal mortality and morbidity. Early recognition of women at risk of pre-eclampsia will enable the identification of high-risk women who may benefit from enhanced surveillance and prophylaxis. In this chapter, we summarise the accuracy of various tests used to predict the onset of pre-eclampsia and the effectiveness of preventative treatment. The tests used to predict pre-eclampsia include clinical history, examination findings, laboratory and haemodynamic tests. In general, tests in early pregnancy for predicting later development of pre-eclampsia have better specificity than sensitivity, as Body Mass Index greater than 34, alpha-fetoprotein, fibronectin and uterine artery Doppler (bilateral notching) all have specificities above 90%. Only uterine artery Doppler resistance index and combinations of indices have a sensitivity of over 60%. Test such as kallikreinuria not used in clinical practice, has shown high sensitivity above 80%, without compromising specificity, and require further investigation. None of the tests are sufficiently accurate to recommend them for routine use in clinical practice. The various treatment options for preventing pre-eclampsia include pharmacological agents, dietary supplementation and lifestyle modification. Antiplatelet agents, primarily low-dose aspirin, reduce the risk of pre-eclampsia by 10% (RR 0.90, 95% CI 0.84 to 0.97). Calcium effectively prevents pre-eclampsia (RR 0.45, 95% CI 0.31 to 0.65); the beneficial effect being observed in the high-risk group (RR 0.22; 95% CI 0.12 to 0.42) and in the group with low nutritional calcium intake (RR 0.36, 95% CI 0.20 to 0.65). Pharmacological agents, such as low molecular weight heparin, progesterone, nitric oxide donors, anti-hypertensive medication and diuretics are not effective in preventing pre-eclampsia. Dietary supplements, such as magnesium, anti-oxidants, marine oils and folic acid, do not reduce the incidence of pre-eclampsia. Evidence is lacking to support lifestyle preventative interventions for pre-eclampsia, such as rest, exercise and reduced dietary salt intake.

摘要

子痫前期与母婴围产期发病率和死亡率增加有关。早期识别有子痫前期风险的妇女,将有助于确定可能受益于加强监测和预防的高危妇女。在本章中,我们总结了用于预测子痫前期发作的各种检测方法的准确性和预防治疗的有效性。用于预测子痫前期的检测方法包括临床病史、检查结果、实验室和血液动力学检测。一般来说,用于预测妊娠后期子痫前期发生的早期检测方法具有更好的特异性,而非敏感性,因为体重指数大于 34、甲胎蛋白、纤维连接蛋白和子宫动脉多普勒(双侧切迹)的特异性均大于 90%。只有子宫动脉多普勒阻力指数和指数组合的敏感性超过 60%。在临床实践中未使用的 kallikreinuria 等检测方法,其敏感性超过 80%,而特异性不受影响,需要进一步研究。没有一种检测方法足够准确,可以推荐用于临床实践中的常规使用。预防子痫前期的各种治疗选择包括药物治疗、饮食补充和生活方式改变。抗血小板药物,主要是低剂量阿司匹林,可使子痫前期的风险降低 10%(RR 0.90,95%CI 0.84 至 0.97)。钙可有效预防子痫前期(RR 0.45,95%CI 0.31 至 0.65);这种有益作用在高危组(RR 0.22;95%CI 0.12 至 0.42)和低营养钙摄入组(RR 0.36,95%CI 0.20 至 0.65)中观察到。低分子肝素、孕酮、一氧化氮供体、抗高血压药物和利尿剂等药物治疗在预防子痫前期方面无效。镁、抗氧化剂、海洋油和叶酸等膳食补充剂并不能降低子痫前期的发病率。缺乏证据支持针对子痫前期的生活方式预防干预措施,如休息、运动和减少膳食盐摄入。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验